{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:15:56Z","timestamp":1783966556817,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Peripheral T-cell lymphoma (PTCL) is an aggressive disease with a poor prognosis. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent, has been approved for the treatment of PTCL. We evaluated a new effective combination partner of BV using non-clinical approaches that could potentially identify agents capable of improving survival times for patients with PTCL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A high-throughput screening test was used to select the most synergistic partner of BV from 14 candidate drugs that were under development or available in clinical practice for PTCL. HH cells, originating from an aggressive cutaneous T-cell lymphoma, were used as an experimental model of PTCL. Apoptotic effects of the synergistic partner of BV were further investigated in vitro and in vivo using HH-cell xenograft mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Chidamide (tucidinostat), a novel histone deacetylase inhibitor, was found to have the greatest synergistic effect with BV on HH cells. The combined effects of chidamide and BV were demonstrated in a study of HH-cell xenograft mice; mean tumor size following combined treatment was 22% of that observed in the control group, compared with 71% and 58% following chidamide and BV monotherapy, respectively. Further investigations in vitro and in vivo revealed that the levels of an anti-apoptotic protein, Bcl-2, and a rate-limiting factor of DNA replication, <jats:italic>CDC45<\/jats:italic>, were reduced in HH cells treated with chidamide combined with BV compared with the control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of chidamide in conjunction with BV may positively affect and enhance T-cellular apoptotic pathways without offsetting each other.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-023-04609-5","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:01:39Z","timestamp":1698998499000},"page":"137-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2174-0393","authenticated-orcid":false,"given":"Yukio","family":"Tonozuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Kakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"4609_CR1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ijc.29477","volume":"137","author":"D Chihara","year":"2015","unstructured":"Chihara D, Ito H, Izutsu K, Hattori M, Nishino Y, Ioka A, Matsuda T, Ito Y (2015) Advance and stagnation in the treatment of patients with lymphoma and myeloma: analysis using population-based cancer registry data in Japan from 1993 to 2006. Int J Cancer 137:1217\u20131223. https:\/\/doi.org\/10.1002\/ijc.29477","journal-title":"Int J Cancer"},{"key":"4609_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/1179545X17705863","author":"C Hildyard","year":"2017","unstructured":"Hildyard C, Shiekh S, Browning J, Collins GP (2017) Toward a biology-driven treatment strategy for peripheral T-cell lymphoma. Clin Med Insights Blood Disord. https:\/\/doi.org\/10.1177\/1179545X17705863","journal-title":"Clin Med Insights Blood Disord"},{"issue":"Suppl 5","key":"4609_CR3","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F D'Amore","year":"2015","unstructured":"D\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M, ESMO Guidelines Committee (2015) Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v108-115. https:\/\/doi.org\/10.1093\/annonc\/mdv201","journal-title":"Ann Oncol"},{"key":"4609_CR4","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117:5827\u20135834. https:\/\/doi.org\/10.1182\/blood-2010-10-312603","journal-title":"Blood"},{"key":"4609_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/jco.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182\u20131189. https:\/\/doi.org\/10.1200\/jco.2010.29.9024","journal-title":"J Clin Oncol"},{"key":"4609_CR6","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/jco.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190\u20132196. https:\/\/doi.org\/10.1200\/jco.2011.38.0402","journal-title":"J Clin Oncol"},{"key":"4609_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458\u20131465. https:\/\/doi.org\/10.1182\/blood-2003-01-0039","journal-title":"Blood"},{"key":"4609_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","volume":"14","author":"K Karube","year":"2021","unstructured":"Karube K, Kakimoto Y, Tonozuka Y, Ohshima K (2021) The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol 14:777\u2013787. https:\/\/doi.org\/10.1080\/17474086.2021.1955344","journal-title":"Expert Rev Hematol"},{"key":"4609_CR9","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/jco.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32:3137\u20133143. https:\/\/doi.org\/10.1200\/jco.2013.54.2456","journal-title":"J Clin Oncol"},{"key":"4609_CR10","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","volume":"131","author":"MA Fanale","year":"2018","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR (2018) Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood 131:2120\u20132124. https:\/\/doi.org\/10.1182\/blood-2017-12-821009","journal-title":"Blood"},{"key":"4609_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Ill\u00e9s \u00c1, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, H\u00fcttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Tr\u00fcmper L (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393:229\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2","journal-title":"Lancet"},{"key":"4609_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Ill\u00e9s \u00c1, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, H\u00fcttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T (2022) The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33:288\u2013298. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002","journal-title":"Ann Oncol"},{"key":"4609_CR13","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2013","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, Siddiqi T, Kennedy DA, Oki Y (2013) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095\u20133100. https:\/\/doi.org\/10.1182\/blood-2013-12-542142","journal-title":"Blood"},{"key":"4609_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dr\u00e9no B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M, ALCANZA study group, (2017) Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555\u2013566. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"4609_CR15","first-page":"34","volume":"101","author":"WD Lewis","year":"2020","unstructured":"Lewis WD, Lilly S, Jones KL (2020) Lymphoma: diagnosis and treatment. Am Fam Physician 101:34\u201341","journal-title":"Am Fam Physician"},{"key":"4609_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","volume":"1711","author":"L He","year":"2018","unstructured":"He L, Kulesskiy E, Saarela J, Turunen L, Wennerberg K, Aittokallio T, Tang J (2018) Methods for high-throughput drug combination screening and synergy scoring. Methods Mol Biol 1711:351\u2013398. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_17","journal-title":"Methods Mol Biol"},{"key":"4609_CR17","unstructured":"R Core Team (2022) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. Accessed 7 Nov 2022"},{"key":"4609_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"key":"4609_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/C5MB00663E","volume":"12","author":"G Yu","year":"2016","unstructured":"Yu G, He QY (2016) ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst 12:477\u2013479. https:\/\/doi.org\/10.1039\/C5MB00663E","journal-title":"Mol Biosyst"},{"key":"4609_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"4609_CR21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 14:1376\u20131384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0036","journal-title":"Mol Cancer Ther"},{"key":"4609_CR22","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-18-0268","volume":"24","author":"M Nakashima","year":"2018","unstructured":"Nakashima M, Yamochi T, Watanabe M (2018) characterizes polylobated lymphocytes and disease progression in HTLV-1-infected individuals. Clin Cancer Res 24:5445\u20135457. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0268","journal-title":"Clin Cancer Res"},{"key":"4609_CR23","doi-asserted-by":"publisher","first-page":"95981","DOI":"10.18632\/oncotarget.21619","volume":"8","author":"E Netchiporouk","year":"2017","unstructured":"Netchiporouk E, Gantchev J, Tsang M, Thibault P, Watters AK, Hughes JM, Ghazawi FM, Woetmann A, \u00d8dum N, Sasseville D, Litvinov IV (2017) Analysis of CTCL cell lines reveals important differences between mycosis fungoides\/S\u00e9zary syndrome vs HTLV-1+ leukemic cell lines. Oncotarget 8:95981\u2013959998. https:\/\/doi.org\/10.18632\/oncotarget.21619","journal-title":"Oncotarget"},{"key":"4609_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1042\/BJ20111685","volume":"443","author":"K Gong","year":"2012","unstructured":"Gong K, Xie J, Yi H, Li W (2012) CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J 443:735\u2013746. https:\/\/doi.org\/10.1042\/BJ20111685","journal-title":"Biochem J"},{"key":"4609_CR25","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.biopha.2016.08.023","volume":"83","author":"Z Liu","year":"2016","unstructured":"Liu Z, Ding K, Li L, Liu H, Wang Y, Liu C, Fu R (2016) A novel histone deacetylase inhibitor chidamide induces G0\/G1 arrest and apoptosis in myelodysplastic syndromes. Biomed Pharmacother 83:1032\u20131037. https:\/\/doi.org\/10.1016\/j.biopha.2016.08.023","journal-title":"Biomed Pharmacother"},{"key":"4609_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2017.04.037","volume":"90","author":"X Li","year":"2017","unstructured":"Li X, Yan X, Guo W, Huang X, Huang J, Yu M, Ma Z, Xu Y, Huang S, Li C, Zhou Y, Jin J (2017) Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Biomed Pharmacother 90:699\u2013704. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.037","journal-title":"Biomed Pharmacother"},{"key":"4609_CR27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2217\/pgs-2017-0061","volume":"18","author":"P Shi","year":"2017","unstructured":"Shi P, Zhang L, Chen K, Jiang Z, Deng M, Zha J, Guo X, Li P, Xu B (2017) Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage. Pharmacogenomics 18:1259\u20131270. https:\/\/doi.org\/10.2217\/pgs-2017-0061","journal-title":"Pharmacogenomics"},{"key":"4609_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10637-017-0552-y","volume":"36","author":"J Zhou","year":"2018","unstructured":"Zhou J, Zhang C, Sui X, Cao S, Tang F, Sun S, Wang S, Chen B (2018) Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK\/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. Invest New Drugs 36:571\u2013580. https:\/\/doi.org\/10.1007\/s10637-017-0552-y","journal-title":"Invest New Drugs"},{"key":"4609_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3892\/ol.2019.10301","volume":"18","author":"XG Yuan","year":"2019","unstructured":"Yuan XG, Huang YR, Yu T, Jiang HW, Xu Y, Zhao XY (2019) Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. Oncol Lett 18:411\u2013419. https:\/\/doi.org\/10.3892\/ol.2019.10301","journal-title":"Oncol Lett"},{"key":"4609_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113169","volume":"215","author":"A Singh","year":"2021","unstructured":"Singh A, Chang TY, Kaur N, Hsu KC, Yen Y, Lin TE, Lai MJ, Lee SB, Liou JP (2021) CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. Eur J Med Chem 215:113169. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113169","journal-title":"Eur J Med Chem"},{"key":"4609_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2174\/1389201023378265","volume":"3","author":"P Decker","year":"2002","unstructured":"Decker P, Muller S (2002) Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3:275\u2013283. https:\/\/doi.org\/10.2174\/1389201023378265","journal-title":"Curr Pharm Biotechnol"},{"key":"4609_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1080\/15384101.2016.1152424","volume":"15","author":"C K\u00f6hler","year":"2016","unstructured":"K\u00f6hler C, Koalick D, Fabricius A, Parplys AC, Borgmann K, Pospiech H, Grosse F (2016) Cdc45 is limiting for replication initiation in humans. Cell Cycle 15:974\u2013985. https:\/\/doi.org\/10.1080\/15384101.2016.1152424","journal-title":"Cell Cycle"},{"issue":"1","key":"4609_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/cad.0000000000001008","volume":"32","author":"RM Makena","year":"2021","unstructured":"Makena RM, Nguyen HT, Koneru B, Hindle A, Chen WH, Verlekar DU, Kang MH, Reynolds CP (2021) Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. Anticancer Drugs 32(1):34\u201343. https:\/\/doi.org\/10.1097\/cad.0000000000001008","journal-title":"Anticancer Drugs"},{"issue":"9","key":"4609_CR34","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","volume":"21","author":"S Jain","year":"2015","unstructured":"Jain S, Jirau-Serrano X, Zullo MK, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O\u2019Connor OA (2015) Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res 21(9):2096\u20132106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2249","journal-title":"Clin Cancer Res"},{"key":"4609_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP (2012) Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 69:901\u2013909. https:\/\/doi.org\/10.1007\/s00280-011-1766-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"4609_CR36","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3389\/fimmu.2018.01799","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang X, Fan J, Chen W, Luan J, Nan Y, Wang S, Chen Q, Zhang Y, Wu Y, Ju D (2018) Activating autophagy enhanced the antitumor effect of antibody drug conjugates rituximab-monomethyl auristatin E. Front Immunol 9:1799. https:\/\/doi.org\/10.3389\/fimmu.2018.01799","journal-title":"Front Immunol"},{"key":"4609_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","volume":"8","author":"MW Chao","year":"2015","unstructured":"Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM (2015) The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol 8:82\u201397. https:\/\/doi.org\/10.1186\/s13045-015-0176-7","journal-title":"J Hematol Oncol"},{"key":"4609_CR38","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","volume":"130","author":"BM Cyrenne","year":"2017","unstructured":"Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M (2017) Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 130:2073\u20132083. https:\/\/doi.org\/10.1182\/blood-2017-06-792150","journal-title":"Blood"},{"key":"4609_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M (2015) Histone deacetylase inhibitors for cutaneous T-cell lymphoma. Dermatol Clin 33:757\u2013764. https:\/\/doi.org\/10.1016\/j.det.2015.05.010","journal-title":"Dermatol Clin"},{"key":"4609_CR40","doi-asserted-by":"publisher","first-page":"10236","DOI":"10.1073\/pnas.060240010","volume":"103","author":"SE Moyer","year":"2006","unstructured":"Moyer SE, Lewis PW, Botchan MR (2006) Isolation of the Cdc45\/Mcm2-7\/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci U S A 103:10236\u201310241. https:\/\/doi.org\/10.1073\/pnas.060240010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4609_CR41","first-page":"7356","volume":"63","author":"D Feng","year":"2003","unstructured":"Feng D, Tu Z, Wu W, Liang C (2003) Inhibiting the expression of DNA replication-initiation proteins induces apoptosis in human cancer cells. Cancer Res 63:7356\u20137364","journal-title":"Cancer Res"},{"issue":"1","key":"4609_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang J, Jiang Q, Zhang L, Song W (2018) Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem 33(1):714\u2013721. https:\/\/doi.org\/10.1080\/14756366.2017.1417274","journal-title":"J Enzyme Inhib Med Chem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04609-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:03:52Z","timestamp":1707368632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04609-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4609"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04609-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yukio Tonozuka, Kazumi Nomura, Junpei Soeda, and Yoshihide Kakimoto are employees of Takeda Pharmaceutical Co. Ltd. Hiroshi Tanaka and Kazuya Sakaguchi are employees of Axcelead Drug Discovery Partners, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Shonan Health Innovation Park accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}